Abstract
AbstractBackgroundTelmisartan (TLT) is a prototypic angiotensin receptor blocker largely used to treat hypertension worldwide. In addition to its cardioprotective effects, TLT presents pleiotropic activities and notably displays noticeable anti-inflammatory and antitumor effects. The repression of the programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) immune checkpoint may be implicated antitumor action of TLT, as it is the case with many other compounds equipped with a biphenyl moiety. We have used molecular modeling to compare the interaction of TLT and derivatives with the PD-L1 dimer protein.ResultsTwo molecules, TLT-dimer and TLT-acylglucuronide, were found to form more stable complexes with PD-L1 than TLT itself. In parallel, the docking analysis performed with a series of 12 sartans led to the identification of Olmesartan as a potential PD-L1 binder. The stacked biphenyl unit of Olmesartan positions the molecule along the groove delimited by the two protein monomers. The flanking tetrazole and imidazole moieties, on each side of the biphenyl unit of Olmesartan, contribute favorably to the protein interaction via specific hydrogen bonding interactions.ConclusionsThe computational analysis suggests a possible binding of Olmesartan to PD-L1 dimer and thus offers novel perspectives for the design of small molecules capable of interrupting the PD-1/PD-L1 immune checkpoint. Experimental studies are warranted to validate the hypothesis.Graphical abstract
Publisher
Springer Science and Business Media LLC
Reference89 articles.
1. Abdelkader NN, Awaisu A, Elewa H, El Hajj MS (2023) Prescribing patterns of antihypertensive medications: a systematic review of literature between 2010 and 2020. Explor Res Clin Soc Pharm 11:100315
2. Kumari K, Toppo MS, Majhi L, Kumar A (2022) Blood pressure-lowering effect of telmisartan compared to losartan among mild to moderate essential hypertensive adult subjects: a meta-analysis. J Family Med Prim Care 11:6227–6235
3. Telmisartan market (2022) https://straitsresearch.com/report/telmisartan-market
4. Kjeldsen S, Mancia G, Schmieder R, Mattheus M, Unger T (2013) An update on telmisartan/hydrochlorothiazide combinations for the management of hypertensive patients with additional cardiovascular risk factors. Expert Rev Cardiovasc Ther 11:673–682
5. Kjeldsen SE, Schumacher H, Neldam S, Guthrie RM (2013) Telmisartan/Hydrochlorothiazide combination therapy for the treatment of hypertension: a pooled analysis in older and younger patients. J Clin Hypertens (Greenwich) 15:380–388